AI Trends in U.S. Healthcare & Life Sciences: The $100 Billion Race Reshaping Medicine

The U.S. healthcare and life sciences industry is entering a new phase.

For years, hospitals, pharmaceutical companies, insurers, and biotech firms collected massive amounts of data but struggled to convert it into faster decisions and better patient outcomes.

Today, artificial intelligence is changing that reality.

From drug discovery and clinical trials to diagnostics, medical imaging, patient engagement, and hospital operations, AI is becoming a core business tool rather than an experimental technology. More than 85% of U.S. healthcare organizations are already exploring or using AI capabilities, while many have moved beyond pilot projects into large-scale implementation.

More than 1,200 AI-enabled medical devices have now received authorization from the U.S. FDA, making healthcare one of the fastest-growing AI sectors in the country. Radiology alone accounts for over 1,100 approved AI devices, demonstrating how quickly medical imaging has embraced AI technology.

industry estimates, the global healthcare AI market was valued at approximately $38 billion in 2025 and is projected to grow at nearly 38% CAGR through 2035, with the U.S. remaining the largest market.

Key U.S. Healthcare AI Statistics

Big Pharma Is Spending Billions

The world’s largest healthcare companies are investing heavily because AI can shorten drug development timelines and reduce costs.

Johnson & Johnson

Johnson & Johnson reported approximately $88.8 billion in revenue during 2024 while spending more than $17 billion annually on R&D.

The company evaluated nearly 900 AI use cases across research, commercial operations, and supply chains before focusing on the 10%-15% of projects generating the highest business value.

Pfizer

Pfizer invests approximately $10 billion–$11 billion annually in research and development.

The company uses AI to identify drug targets, optimize clinical trials, and accelerate molecule discovery, reducing research timelines that traditionally take years.

Bristol Myers Squibb

Bristol Myers Squibb has expanded AI-driven commercialization efforts through its AI-powered Mosaic platform, designed to create medical content and support physician engagement more efficiently.

NVIDIA’s Healthcare Push

NVIDIA has become a critical infrastructure provider for healthcare AI.

Its healthcare partnerships span hospitals, biotech firms, pharmaceutical companies, and medical device manufacturers developing AI-powered diagnostics and clinical tools.

Where AI Is Delivering Results

Drug Discovery

Traditional drug development often costs more than $1 billion and can take 10-15 years.

AI models can screen millions of molecular combinations in weeks, helping researchers identify promising candidates faster.

Medical Imaging

Radiology has become the largest AI application area.

AI systems now assist in detecting:

• Lung cancer
• Breast cancer
• Stroke
• Brain hemorrhage
• Cardiovascular disease

Researchers analyzing FDA approvals found that quantitative image analysis remains the dominant healthcare AI use case.

Administrative Efficiency

Healthcare workers spend significant time on documentation.

AI-powered systems can automate:

• Clinical note generation
• Medical coding
• Prior authorization workflows
• Claims processing
• Patient scheduling

Hospitals report productivity gains and reduced physician burnout after implementation.

Benefits for U.S. Healthcare Companies

Whether you’re looking for regional insights, detailed segments, competitor analysis, government data, or market trends, our experts provide customized sample reports for FREE; Download Now: https://www.towardshealthcare.com/download-sample/6001

Challenges and Risks

The AI opportunity is massive, but so are the risks.

Safety Concerns

Reports submitted to regulators show that some AI-enabled devices have experienced malfunctions and adverse events.

Investigations found over 100 reported incidents involving one AI-assisted surgical navigation system, including injuries linked to inaccurate guidance.

Cybersecurity Risks

Connected medical devices create larger attack surfaces for cybercriminals.

Researchers warn that compromised AI models could affect diagnostic accuracy and patient safety.

Regulatory Challenges

The FDA continues expanding guidance for AI-enabled medical devices to address transparency, bias, performance monitoring, and lifecycle management.

Winners in the Next Five Years

The biggest winners may not be hospitals.

Many analysts believe the largest value will flow to:

• AI drug discovery companies
• Medical imaging software firms
• Healthcare cloud providers
• Semiconductor companies supplying AI infrastructure
• Life sciences software providers

Companies that combine healthcare expertise, proprietary data, and AI capabilities are expected to capture the greatest share of future growth.

The U.S. healthcare system generates trillions of dollars in annual spending. As AI adoption expands across hospitals, pharmaceutical companies, insurers, and biotech firms, the industry is moving from isolated AI projects to enterprise-wide transformation. The result is a market where billions of dollars in investment today could create tens of billions in new value over the coming decade.